Published in Ups J Med Sci on February 21, 2012
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev (2006) 14.36
The Polycomb complex PRC2 and its mark in life. Nature (2011) 11.97
Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer (2006) 11.48
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
The molecular classification of multiple myeloma. Blood (2006) 8.77
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
Stem cells and cancer; the polycomb connection. Cell (2004) 7.43
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
The insulin-like growth factor system and cancer. Cancer Lett (2003) 4.91
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol (2005) 3.93
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res (2008) 3.57
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A (2010) 3.16
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2002) 3.02
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res (2004) 2.90
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A (2000) 2.81
Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A (1993) 2.58
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood (2010) 2.42
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood (2003) 2.23
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res (2007) 2.19
Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem (2002) 2.15
Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol (2007) 2.14
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia (2011) 2.12
EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat (2006) 1.92
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood (2000) 1.81
Monoclonal gammopathy of undetermined significance. Br J Haematol (2006) 1.76
Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis (2011) 1.70
Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood (2002) 1.68
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol (2008) 1.64
Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res (1999) 1.63
SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal (2010) 1.63
IGF-1 receptor inhibitors in clinical trials--early lessons. J Mammary Gland Biol Neoplasia (2008) 1.62
Chromatin states in pluripotent, differentiated, and reprogrammed cells. Curr Opin Genet Dev (2011) 1.62
Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia (2008) 1.56
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood (2010) 1.51
In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood (2004) 1.43
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica (2010) 1.42
Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res (2010) 1.36
Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood (2003) 1.33
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood (2005) 1.29
Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev (2003) 1.27
Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin Investig Drugs (2011) 1.26
The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J (2000) 1.25
Polycomb target genes are silenced in multiple myeloma. PLoS One (2010) 1.21
Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood (1996) 1.21
The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer (2007) 1.20
Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood (2000) 1.17
The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood (2001) 1.17
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia (1994) 1.16
Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia (2002) 1.15
Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother (2006) 1.15
Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia (2006) 1.12
Clinical implication of centrosome amplification in plasma cell neoplasm. Blood (2005) 1.11
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood (2005) 1.11
The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells. Cancer Res (2010) 1.09
IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood (2010) 1.04
Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model. Leukemia (2012) 1.01
Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer (2007) 1.00
Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood (2002) 0.99
A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol (1997) 0.98
Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines. Leukemia (1991) 0.98
Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res (2000) 0.96
Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia (2005) 0.95
Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9. Biochem Biophys Res Commun (2010) 0.92
Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol (2010) 0.90
The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. Blood (1999) 0.90
The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin. Clin Cancer Res (2012) 0.88
Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood (1999) 0.87
Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. Expert Rev Anticancer Ther (2005) 0.86
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol (2008) 0.85
The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. Oncogene (2006) 0.84
The 5T2MM murine model of multiple myeloma: maintenance and analysis. Methods Mol Med (2005) 0.84
Perspectives on the origins of multiple myeloma and plasmacytomas in mice. Hematol Oncol Clin North Am (1992) 0.82
IL-6 as a growth factor for human multiple myeloma cells--a short overview. Curr Top Microbiol Immunol (1990) 0.82
Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP). PLoS One (2011) 0.81
Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I). Adv Cancer Res (2007) 0.79
The effects on growth and survival of IL-6 can be dissociated in the U-266-1970/U-266-1984 and HL407E/HL407L human multiple myeloma cell lines. Br J Haematol (1997) 0.78
The in vitro effect of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol (1985) 0.77
The control of proliferation, survival and apoptosis in human multiple myeloma cells in vitro. Curr Top Microbiol Immunol (1999) 0.76
Homing of the myeloma cell clone. Acta Oncol (2000) 0.75
Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood (2003) 1.33
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood (2005) 1.29
Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival. Eur J Haematol (2002) 1.28
Polycomb target genes are silenced in multiple myeloma. PLoS One (2010) 1.21
Dissemination of spotted fever rickettsia agents in Europe by migrating birds. PLoS One (2010) 1.19
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood (2005) 1.11
Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer (2003) 1.04
Detection and prevalence of Anaplasma phagocytophilum and Rickettsia helvetica in Ixodes ricinus ticks in seven study areas in Sweden. Parasit Vectors (2010) 1.03
Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer (2007) 1.00
Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology (2003) 0.97
Rickettsia felis infection in Sweden: report of two cases with subacute meningitis and review of the literature. Scand J Infect Dis (2010) 0.96
Prevalence of Rickettsia spp., Anaplasma phagocytophilum, and Coxiella burnetii in adult Ixodes ricinus ticks from 29 study areas in central and southern Sweden. Ticks Tick Borne Dis (2012) 0.95
Seroprevalence of Rickettsia spp. infection among tick-bitten patients and blood donors in Sweden. Scand J Infect Dis (2007) 0.95
Ser727/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0/G1 arrest of U-937 cells. Blood (2003) 0.93
Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma. Exp Hematol (2008) 0.92
Recognition by symmetry derivatives and the generalized structure tensor. IEEE Trans Pattern Anal Mach Intell (2004) 0.91
Molecular characterization of neoplastic and normal "sister" lymphoblastoid B-cell lines from chronic lymphocytic leukemia. Leuk Lymphoma (2013) 0.90
IFN-gamma-induced upregulation of Fcgamma-receptor-I during activation of monocytic cells requires the PKR and NFkappaB pathways. Mol Immunol (2006) 0.88
Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma. BMC Cancer (2012) 0.85
Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells. Blood (2005) 0.84
Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines. Anticancer Drugs (2004) 0.84
Occupational exposure and severe pulmonary fibrosis. Respir Med (2007) 0.83
Tumor-initiating cells in childhood neuroblastoma--letter. Cancer Res (2012) 0.81
Effects of smoking, gender and occupational exposure on the risk of severe pulmonary fibrosis: a population-based case-control study. BMJ Open (2014) 0.81
Positive histone marks are associated with active transcription from a methylated ICSBP/IRF8 gene. Gene (2008) 0.81
Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. Leuk Res (2004) 0.80
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia. Eur J Haematol (2004) 0.80
Retinoic acid inhibits in vitro development of mast cells but has no marked effect on mature human skin tryptase- and chymase-positive mast cells. J Invest Dermatol (2003) 0.80
Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Respir Med (2007) 0.79
Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I). Adv Cancer Res (2007) 0.79
Large-scale protein profiling in human cell lines using antibody-based proteomics. J Proteome Res (2011) 0.78
Improvement of European translational cancer research. Collaboration between comprehensive cancer centers. Tumori (2008) 0.78
PML/RARalpha plays a role for basal activity and retinoid-induced repression of the tissue factor promoter in acute promyelocytic leukemia cells. Thromb Haemost (2003) 0.78
Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828. Anticancer Drugs (2004) 0.77
Life cycle, growth characteristics and host cell response of Rickettsia helvetica in a Vero cell line. Exp Appl Acarol (2011) 0.77
Differentiation-associated redox-regulation in human B cell lines from stem cell/pro-B to plasma cell. Immunol Lett (2004) 0.76
A biometric approach to laboratory rodent identification. Lab Anim (NY) (2007) 0.75
[The Medical Society's Meeting 2001: A national cancer program is required to meet the alarming increase of cancer cases]. Lakartidningen (2002) 0.75
No evidence of Chlamydophila spp. or other intracellular bacteria in mitral valves. Int J Cardiol (2012) 0.75
Trypanosoma spp. in Swedish game animals. Parasitol Res (2011) 0.75
Suppressed signal transduction in the bronchial epithelium of patients with systemic sclerosis. Respir Med (2008) 0.75